Comparable and consistent efficacy responses with up to 3 years of guselkumab treatment in patients with moderate-to-severe plaque psoriasis regardless of prior treatment: Pooled analysis from the VOYAGE 1 and VOYAGE 2 trials
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.